Curis Lifesciences Ipo
Curis Lifesciences IPO Review & Key Points
Review:
IPO Lead Managers aka Merchant Bankers
Finaax Capital Advisors Private Limited
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 2,000 | ₹2,56,000 |
| Retail Maximum | 2 | 2,000 | ₹2,56,000 |
| S-HNI Minimum | 3 | 3,000 | ₹3,84,000 |
| S-HNI Maximum | 7 | 7,000 | ₹8,96,000 |
| B-HNI Minimum | 8 | 8,000 | ₹10,24,000 |
| Investor Category | Share Offered | -% Shares |
| Anchor Investor | 6,10,000 Shares | 28.37% |
| QIB (Ex. Anchor) | 4,08,000 Shares | 18.98% |
| NII Shares Offered | 3,08,000 Shares | 14.33% |
| Retail Shares Offered | 7,16,000 Shares | 33.30% |
| Anchor Bidding Date | November 6, 2025 |
| Anchor Investors List | |
| Shares Offered | 6,10,000 Shares |
| Anchor Size | 7.81 Cr. |
| lock-in period end date 50% shares (30 Days) | December 12, 2025 |
| lock-in period end date 50% shares (90 Days) | February 10, 2026 |
| IPO Open Date: | November 7, 2025 |
| IPO Close Date: | November 11, 2025 |
| Basis of Allotment: | November 12, 2025 |
| Refunds: | November 13, 2025 |
| Credit to Demat Account: | November 13, 2025 |
| IPO Listing Date: | November 14, 2025 |
| IPO Bidding Cut-off Time: | November 11, 2025 – 5 PM |
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 59,34,434 | 92.68% |
| Promoter Holding Post Issue | 80,84,434 | 68.03% |
| Purpose | Crores |
| Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities | ₹2.44 |
| Capital Expenditure towards Construction of a Storage Facility | ₹3.62 |
| Pre-payment/Repayment of outstanding Secured Loans | ₹1.86 |
| Product Registrations in other countries | ₹2.69 |
| Funding our Working Capital Requirements | ₹11.25 |
| General Corporate Purposes |
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ₹36.42 | ₹34.23 | ₹1.88 | ₹29.75 |
| 2024 | ₹35.87 | ₹28.70 | ₹4.87 | ₹33.88 |
| 2025 | ₹49.65 | ₹41.38 | ₹6.11 | ₹42.53 |
| July 2025 | ₹19.51 | ₹15.79 | ₹2.87 | ₹56.29 |
| KPI | Values |
| ROE: | 55.25% |
| ROCE: | 27.83% |
| EBITDA Margin: | 19.41% |
| PAT Margin: | 12.43% |
| Debt to equity ratio: | 0.96 |
| Earning Per Share (EPS): | ₹10.29 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 37.62% |
| Net Asset Value (NAV): | ₹27.34 |
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Sotac Pharmaceuticals Limited | 4.32 | 18.30 | 9.00% | 47.99 | 64.76 Cr. |
| Lincoln Pharmaceuticals Limited | 41.11 | 12.21 | 12.27% | 335.34 | 645.71 Cr. |
| IPO Open Date | November 7, 2025 |
| IPO Close Date | November 11, 2025 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹120 to ₹128 Per Share |
| Issue Size | Approx ₹27.52 Crores |
| Fresh Issue | Approx ₹27.52 Crores |
| Issue Type | Book Built Issue |
| IPO Listing | NSE SME |
| DRHP Draft Prospectus | |
| RHP Draft Prospectus |